Impact Factor 3.634 | CiteScore 3.51
More on impact ›

Mini Review ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Endocrinol. | doi: 10.3389/fendo.2019.00565

Clinical Implications and Impact of Discovery of the Thyroid Hormone Receptor on Integrin αvβ3 - A Review

  • 1Cleveland Clinic, United States

Hypothyroidism has been reported to improve survival in cancer patients but only recently has the putative mechanism been identified as a receptor for thyroxine and tri-iodothyronine on integrin αvβ3. Recognition of divergence of action of the pro-oncogenic L-thyroxine (T4) from pro-metabolic 3,5,3’-triiodo-L-thyronine (T3) has enabled clinical implementation whereby exogenous T3 may replace exogenous (or endogenous) T4 to maintain clinical euthyroid hypothyroxinemia that results in significantly better survival in advanced cancer patients without the morbidity of clinical hypothyroidism.

Keywords: Hypothyroidism, Cancer, L-thyroxine (L-T4), Integrin αvβ3, Thyroid hormone receptor (TR), euthyroid hypothyroxinemia

Received: 13 May 2019; Accepted: 02 Aug 2019.

Edited by:

Sandra Incerpi, Roma Tre University, Italy

Reviewed by:

Hynda K. Kleinman, School of Medicine and Health Sciences, George Washington University, United States
Roberto De Luca, Beth Israel Deaconess Medical Center, Harvard Medical School, United States  

Copyright: © 2019 Hercbergs. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Dr. Aleck Hercbergs, Cleveland Clinic, Cleveland, Ohio, United States, hercbergs@gmail.com